



>> **Call identifier:**
FP7-HEALTH-2009-single-stage
>> **Date of publication:**
3 September 2008
>> **Deadline:**
3 December 2008
>> **Budget:**
EUR 476 million

>> **Call identifier:**
FP7-Health-2009-two-stage
>> **Date of publication:**
3 September 2008
>> **Deadline for stage 1 proposals:** 3 December 2008
>> **Budget:**
EUR 115 million

>> **Beneficiaries**

- ◆ Research Centres
- ◆ Local & Regional authorities
- ◆ Corporations & SMEs
- ◆ Universities

>> **Website / Information**
http://cordis.europa.eu/fp7/dc/index.cfm?fuseaction=UserSite.FP7DetailsCallPage&call_id=166

CONTEXT

The overall objective of the Health Theme is to improve the health of European citizens and increase the competitiveness and boost the innovative capacity of European health-related industries and businesses, while addressing global health issues including emerging epidemics. Emphasis will be put on translational research (translation of basic discoveries into clinical applications including scientific validation of experimental results), the development and validation of new therapies, strategies for health, promotion and prevention, child health and healthy ageing, diagnostic tools and medical technologies, as well as sustainable and efficient healthcare systems.

Focus on three main strategic axes:

- ◆ Structuring and coordinating research in the context of the European Research Area (ERA)
- ◆ Emphasising translational research and policy-driven research, in line with the specific programme 'Cooperation'.
- ◆ Efforts to structure collaborative research will continue, building on the 6th Framework programme and on the first calls of the 7th Framework programme, where large-scale collaboration at the EU level is essential to exploit the full potential of research for applications to human health.

SME relevant research:

For all areas of work programme 2009, the involvement of industrial participants, in particular research-intensive small and medium-sized enterprises (SME) continues to be encouraged. SME providing services (e.g. management, intellectual property expertise) are also eligible to participate. It is foreseen that future work programmes will include several SME-specific topics.

Funding Scheme and Eligibility Conditions

Minimum Conditions	Funding Scheme	Minimum requested EC contribution	Maximum requested EC contribution
At least 3 independent legal entities each of which is established in a MS or AC and no 2 of which are established in the same MS or AC	Collaborative Projects (Large scale integrating Project)	EUR 6 000 000	EUR 12 000 000
At least 3 independent legal entities each of which is established in a MS or AC and no 2 of which are established in the same MS or AC	Collaborative Projects (Small or medium-scale research Project)		EUR 3 000 000
At least 4 independent legal entities. Of these, 2 must be established in different MS or AC. The other 2 must be established in different international cooperation partner countries (ICPC).	Network of Excellence		EUR 12 000 000
At least 3 independent legal entities, each of which is established in a MS or AC, and no 2 of which are established in the same MS or AC	Coordination and Support Action (Coordinating Action)		EUR 1 500 000
At least 1 independent legal entity	Coordination and Support Action (Supporting Actions)		EUR 500 000

Area	Topic	Stage Call	Funding Scheme	Particular requirements	BUDGET (million)
	1. Biotechnology, Generic Tools and Medical Technologies for Human Health				120 million
1. 1	High-Throughput Research				
1.1-1	Computational tools for Genome annotation and Genotype/ phenotype data integration	2	CP(L)		
1.1-2	High Throughput tools and technologies to analyse samples in large-scale human biobanks	2	CP(L)		
1.1-3	Tools, technologies and resources for the characterisation of protein functions	2	CP(L)		
1.2	Detection, Diagnosis and Monitoring				
1.2-1	Development of tools for sensitive and specific in vitro detection of proteins and their interactions	1	CP(S)	EC contribution <6 million	
1.2-2	Design of methods suited to identify epigenetic factors and their use in the genetic diagnosis of relevant disorders	1	CP(S)		
1.2-3	Novel MR-compatible PET detectors for simultaneous PET/MRI imaging	1	CP(L)		
1.2-4	Novel Imaging systems for in vivo monitoring and quality control during tumour ion beam therapy	1	CP(S)	EC contribution <6 million	
1.2-5	Activatable or smart in vivo imaging agents reporting on physico-chemical or molecular changes	1	CP(S)	EC contribution <6 million	
1.2-6	Evaluation of the potential health impact of diagnostic imaging agents doses	1	CSA	Maximum of 1 project selected	
1.3	Suitability, safety, efficacy and therapies				
1.3-1	New initiatives towards the implementation of the Replace, Reduce and Refine strategy	1	CSA	EC contribution <1 million	
1.4	Innovative therapeutic approaches and interventions				
1.4-1	Cell therapy for tissue and organs	1	CP(L)		
1.4-2	Regeneration of tissue using bio-compatible materials and cells	1	CP(L)		
	2. Translating Research for Human Health				
2.1	Integrating Biological Data and Process				
2.1.1-1	Large scale functional genomics effort in multi-cellular organisms to elucidate the function of human genes products	2	CP(L)		
2.1.1-2	Large scale functional genomics efforts to identify molecular determinants of cancer	2	CP(L)		
2.1.1-3	Characterisation of human genetic variation in Europe	2	CP(L)		
2.1.2-1	Systems biology approaches for basic biological processes relevant to health and disease	2	CP(L)		
2.2	Research on the Brain and related disease, human development and ageing				41 million
2.2.1-1	Synaptopathies: genesis, mechanisms and therapy	1	CP(L)		
2.2.1-2	Identifying genetic and environmental interactions in schizophrenia	1	CP(L)		



2.2.1-3	Optimising current therapeutic approaches to schizophrenia	1	CP(L)		
2.2.1-4	Understanding the blood brain barrier (BBB) to improve drug delivery to the brain	1	CP(S)		
2.2.1-5	Psycho-social factors of brain disorders	1	CSA		
2.3	Translational research in major infectious disease: to confront major threats to public health				75 million
2.3.1-1	Global collaborative research on the prevention of antibiotic resistance	1	CP(L)		
2.3.1-2	Impact of specific antibiotic therapies on the prevalence of resistant bacteria in the human host	1	CP(S)	EC contribution <6 million	
2.3.1-3	Clinical evaluation of point of care diagnostic tests for microbial detection and identification, antibiotic susceptibility determination and biomarkers	1	CP(S)	EC contribution <6 million	
2.3.2-1	Integration of European efforts in research on malaria	1	Network of excellence		
2.3.2-2	Identification and pre-clinical testing of new vaccine	1	CP(L)		
2.3.2-3	Discovery and/or development of new and promising anti-HIV microbicides	1	CP(L)		
2.3.2-4	Mucosal and topical vaccines for poverty-related diseases (HIV-AIDS, malaria and/or TB)	1	CP(S)		
2.3.2-6	ERA-NET for stepping up European cooperation in HIV-AIDS	1	CSA		
2.3.3-1	Efficacy and effectiveness of personal protection equipment and other measures against influenza transmission	1	CP(S)		
2.4	Translational Research in other Major Diseases				95 million
2.4.2-1	Improved or new therapeutic approaches for the treatment of heart failure	1	CP(L)		
2.4.2-2	Cardiac arrhythmias: from genes to improved management of patients	1	CP(L)		
2.4.2-3	Translation of basic knowledge on inherited cardiomyopathies into clinical practice	1	CP(S)		
2.4.3-1	Novel Therapeutical approach to pregnancy-induced diabetes	1	CP(S)		
2.4.3-2	Novel immunotherapies for type 1 diabetes	1	CP(L)		
2.4.3-3	Molecular pathways in food intake at CNS-liver-gut regulation level	1	CP(S)		
2.4.4-1	Rare neurological diseases	1	CP(S)	EC contribution <6 million	
2.4.4-2	Preclinical development of substances with a clear potential as orphan drugs	1	CP(S)		
2.4.5-1	Prevention and treatment of non-alcoholic fatty liver disease	1	CP(S)	EC contribution <6 million	
2.4.5-2	Cellular and molecular mechanisms of the development of chronic kidney disease	1	CP(L)		

3. Optimising the delivery of healthcare to European Citizens					64 million
3.1	Translating the results of clinical research outcome into clinical practice including better use of medicines				
3.1-1	Patient Safety: Effective implementation of prevention strategies for healthcare associated infections	1	CP(S)		
3.1-2	Improve quality and safety of hospital care	1	CP(S)		
3.1-3	Complementary and Alternative medicine	1	CSA		
3.1-4	Improved treatment of chronic diseases in developing countries	1	CP(S)		
3.2	Quality, Efficiency and Solidarity of Healthcare systems including transitional health systems				
3.2-1	Organisation of dementia care	1	CP(S)		
3.2-2	Healthcare outcomes and cost-benefits	1	CP(S)		
3.2-3	Primary care quality linkage to costs	1	CP(S)		
3.2-4	Impact of cross border collaboration on health services	1	CP(S)	EC contribution <6 million	
3.2-5	Research access to comparable healthcare data	1	CSA		
3.2-6	Scoping study to address the methodological challenges of quantifying the socio-economic burden of brain diseases in the enlarged EU	1	CSA		
3.3	Enhanced Health Promotion and Disease Prevention				
3.3-1	Child and Adolescent mental health	1	CP(S)		
3.3-2	Environmental prevention of substance abuse by adolescents	1	CP(S)		
3.3-3	Ageing cohorts	1	CP(L)		
3.3-4	Birth-Mother—Child cohorts coordination	1	CSA		
3.3-5	European Child Health research platform	1	CSA		
4. Other actions across the Health Theme					81 million
4.1-1	Monitoring tool and technology transfer analysis for health grants during FP7	1	CSA	EC contribution <1 million	
4.1-2	Dissemination of results from research in Life Sciences and Biotechnology for health	1	CSA	EC contribution <1 million	
4.1-3	Targeting publication bias	1	CSA		
4.2	Responding to EU Policy needs				
4.2-1	Adapting off-patent medicines to the specific needs of paediatric populations	1	CP(S)	EC contribution <6 million	
4.2-2	Study of the Arrhythmogenic potential of different classes of medicines	1	CP(S)	EC contribution <3 million	
4.2-3	Human Papillomavirus Vaccination (HPV) and cervical cancer screening programmes	1	CP(S)		
4.2-4	Coordination action on an organ procurement and transplantation with a focus on new EU Member States.	1	CSA		
4.3	Specific International Action (SICA)				
4.3.1-1	Discovery and development of new vaccines or drugs for helminth infections			EC contribution <6 million 2 participants from MS or AC and 2 IPCP	



4.3.1-2	Identification and development of vaccine candidates for neglected bacterial infections	1	SICA	EC contribution < 6 million 2 participants from MS or AC and 2 IPCP	
4.3.1-3	Human Immune responses to co-infections of poverty related (HIV, malaria, TB) and neglected infectious diseases	1	SICA	2 participants from MS or AC and 2 ACP	
4.3.2-1	Strategies and interventions for improving reproductive health	1	SICA	2 participants from MS or AC and 2 IPCP	
4.3.2-2	Access to medicines	1	SICA	2 participants from MS or AC and 2 IPCP	
4.3.2-3	Integration of diseases surveillance and health systems responses	1	SICA	2 participants from MS or AC and 2 ACP	
4.3.3-1	Comparative population genetic studies on multifactorial diseases	1	SICA	2 participants from different MS or AC and 2 from Russia	
4.3.3-2	Mechanisms of diabetic and weight related comorbidity in heart failures	1	SICA	2 participants from different MS or AC and 2 from Russia	